24-HOUR MH HOTLINE

800-644-9737

FOR EMERGENCIES ONLY

 

Abstracts

  • Presented to the International Anesthesia Research Society (IARS) 2015:
    Werneid K, Riazi S, Brandom BW: Long-term sequelae in patients who experienced a malignant hyperthermia event.
  • Presented to the American Society of Anesthesiologists (ASA) 2013:
    Larach MG, Brandom BW, Allen GC, Gronert GA: Failure to rescue from fulminant malignant hyperthermia: deaths and their genetic variants 2007-2012.
  • Presented to the American Society of Anesthesiologists (ASA) 2011:
    Brandom BW, Wilde J, Young MC: Chronic pain symptoms in malignant hyperthermia.
  • Presented to the European Malignant Hyperthermia Group 2010:
    Brandom BW, Muldoon, SM, Sambuughin N: More than Anesthetic Induced Malignant Hyperthermia (MH).
  • Presented to the European Malignant Hyperthermia Group 2009:
    Brandom BW, Muldoon SM, Wong C, Rosenberg H, Tautz T, Sambuughin N: An Update on the Ryanodine Receptor Gene Variants found in the USA.
  • Presented to the American Society of Anesthesiologists (ASA) 2008:
    Larach MG, Allen GC, Brandom BW, Gronert GA, Lehman EB: Temperature changes are not late signs of malignant hyperthermia: A NAMH Registry of MHAUS Study
  • Presented to the American Society of Anesthesiologists (ASA) 2008:
    Scientific Papers, in review. Larach MG, Allen GC, Brandom BW, Gronert GA, Lehman EB: Serious complications associated with malignant hyperthermia events: A NAMH Registry of MHAUS Study.
  • Presented to the American Society of Anesthesiologists (ASA) 2007:
    Sambuughin N, Brandom B, Capacchione J, Rosenberg H, Muldoon S: Toward updating the North American Malignant Hyperthermia Mutation Panel.
  • Presented to the American Society of Anesthesiologists (ASA) 2006:
    Larach MG, Brandom BW, Allen GC, Gronert GA, Lehman EB: Deaths associated with malignant hyperthermia (1987-2006). A North American MH Registry of MHAUS Study.
  • Presented to the American Society of Anesthesiologists (ASA) 2005:
    Torp KD, Brandom BW, Capacchione JF, Voelkel ML, Muldoon SM: Caffeine halothane contracture test and ryanodine receptor type 1 analysis in patients who experienced MH episodes.
  • Presented to the American Society of Anesthesiologists (ASA) in 2005:
    Burkman JM, Posner KL, Domino KB: Analysis of the clinical variables associated with recrudescence after malignant hyperthermia reactions.
  • Presented to the American Society of Anesthesiologists (ASA) in 2004:
    Sambuughin N, Holley H, Brandom B, Nelson T, Muldoon S: Comprehensive screening of the RYR1 gene for malignant hyperthermia susceptibility.
  • Presented to the European Congress of Nursing in 2004,
    previously presented to the American Association of Nurse Anesthethists 2003:

    Ciceron MC, Lauriello R, McCarthy EJ, McDonough JP: Differences in clinical manifestations in malignant hyperthermia episodes with succinylcholine or volatile anesthetics.
  • Presented to the Society for Pediatric Anesthesia 2003:
    Brandom BW, Larach MG, Gurgis F: Comparison of pediatric and adult patients with regard to the safety and efficacy of dantrolene.
  • Presented to the American Society of Anesthesiologists 2002:
    Kozack JK: A survey of chronic muscle pain and other symptoms in malignant hyperthermia susceptible individuals.
  • Presented to the American Society of Anesthesiologists 2002:
    Brandom BW, Larach MG: Reassessment of the safety and efficacy of dantrolene.

 

 

 


NEW!! Question about this page or topic?
If you've used the search function at the top of our pages and still haven't
found what you need, use our online form to ask for more information!